Hepatitis C Drug Development at a Crossroads†
Open Access
- 28 September 2009
- journal article
- other
- Published by Wolters Kluwer Health in Hepatology
- Vol. 50 (4) , 997-999
- https://doi.org/10.1002/hep.23208
Abstract
No abstract availableThis publication has 12 references indexed in Scilit:
- Telaprevir and Peginterferon with or without Ribavirin for Chronic HCV InfectionNew England Journal of Medicine, 2009
- Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 InfectionNew England Journal of Medicine, 2009
- 1046 FIRST-IN-MAN DEMONSTRATION OF POTENT ANTIVIRAL ACTIVITY WITH A NUCLEOSIDE POLYMERASE (R7128) AND PROTEASE (R7227/ITMN-191) INHIBITOR COMBINATION IN HCV: SAFETY, PHARMACOKINETICS, AND VIROLOGIC RESULTS FROM INFORM-1Journal of Hepatology, 2009
- Prolonged Therapy of Advanced Chronic Hepatitis C with Low-Dose PeginterferonNew England Journal of Medicine, 2008
- Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patientsHepatology, 2008
- 3‐Drug Synergistic Interactions of Small Molecular Inhibitors of Hepatitis C Virus ReplicationThe Journal of Infectious Diseases, 2008
- Development of novel agents for the treatment of chronic hepatitis C infection: Summary of the FDA Antiviral Products Advisory Committee recommendationsHepatology, 2007
- Telaprevir and pegylated interferon–alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patientsHepatology, 2007
- Predictors of response of U.S. veterans to treatment for the hepatitis C virusHepatology, 2007
- Sustained virological response to interferon-α is associated with improved outcome in HCV-related cirrhosis: A retrospective studyHepatology, 2007